Thoracic cancers
Invited discussant abstracts 425PD, 426PD and 427PD
Date
19 Dec 2015Session
Thoracic cancersPresenters
Ross SooAuthors
R. SooAuthor affiliations
- Department Of Haematology-oncology, National University Health System, National University Cancer Institute, Singapore, 119228 - Singapore/SG
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
View the abstracts discussed:
- Clinical activity and safety of the EGFR mutant-specific inhibitor, BI1482694, in patients (pts) with T790M-positive NSCLC
- Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
- Prognostic significance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Resources from the same session
1227 - Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
Presenter: Leora Horn
Session: Thoracic cancers
Resources:
Abstract
965 - Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC
Presenter: Naiyer Rizvi
Session: Thoracic cancers
Resources:
Abstract
Slides
Webcast
994 - Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3
Presenter: Tony Mok
Session: Thoracic cancers
Resources:
Abstract
529 - Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis
Presenter: Yukio Hosomi
Session: Thoracic cancers
Resources:
Abstract
Invited discussant abstracts 417O and 418O
Presenter: Johan Vansteenkiste
Session: Thoracic cancers
Resources:
Slides
Webcast
Invited discussant abstracts 419O and 420O
Presenter: Daniel Tan
Session: Thoracic cancers
Resources:
Slides
Webcast
1312 - Prospective monitoring of lung function tests with CO and NO diffusion during high dose thoracic radiotherapy for lung cancer: The CONORT study
Presenter: Francoise Mornex
Session: Thoracic cancers
Resources:
Abstract
870 - Local diagnostic practices for advanced non-small-cell lung cancer (NSCLC) in Chinese Patients: subset of the IGNITE study
Presenter: Baohui Han
Session: Thoracic cancers
Resources:
Abstract
804 - A prospective phase III study of three weekly versus weekly paclitaxel as second line therapy in advanced non small cell lung cancer
Presenter: Akhil Kapoor
Session: Thoracic cancers
Resources:
Abstract
702 - Individualization of docetaxel (DTX) treatment in East-Asian advanced non-small cell lung cancer (NSCLC) patients based on pharmacokinetically (PK)-guided dosing strategy: an open-label randomized clinical trial
Presenter: Yuxiang Ma
Session: Thoracic cancers
Resources:
Abstract